• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Takeda launches wearable digital technology IBD pilot program

Takeda launches wearable digital technology IBD pilot program

September 13, 2016
CenterWatch Staff

Takeda Pharmaceuticals U.S.A. announced the launch of a pilot digital technology program to support patients and physicians with the management of inflammatory bowel disease (IBD). Digital approaches are being used to develop solutions across many sectors of healthcare, with cutting-edge technology elevating and transforming disease diagnostics, measurement, treatment and more.

The program, iBData, is designed to intersect healthcare and digital technologies. In partnership with Texas Digestive Disease Consultants (TDDC) and Vanderbilt University Medical Center (VUMC), this pilot program will allow patients with IBD to track their symptoms and lifestyle factors with wearable watch technology. The data will be collected and translated into reports intended to help enhance patient-physician interaction with the goal of improved care.

"The wearable aspect of the technology being used for iBData provides an opportunity to investigate how we as physicians monitor, assess and treat our patients," said Tim Ritter, M.D., medical director, Luminal Research, TDDC.

"We are very excited about this project and its potential for both patients and physicians," said Dawn M. Beaulieu, M.D., assistant professor of medicine, Division of Gastroenterology, Hepatology & Nutrition, VUMC. "Giving patients the power to capture robust, real-time monitoring of their symptoms will help us as physicians to create a personalized treatment plan. Our hope is that this will ultimately result in better disease control and improved IBD care."

The initial rollout of the program will involve approximately 100 patients. iBData aims to improve conversations between patients and physicians in the exam room and between visits, fostering productive and ongoing dialogues, and improve the understanding of individual patients' conditions. This includes analyzing symptoms, triggers and aggravating factors in an effort to expand the ability to treat individuals and potentially improve outcomes.

"At Takeda, part of what fuels our ongoing dedication to advanced research in the field of gastroenterology is our deep understanding of the challenges that dictate unique needs for both patients and physicians managing IBD," explained Stephanie Brown, vice president, head, Specialty Business Unit, Takeda. "iBData leverages the remarkable capabilities available today when wearable technologies and medicine converge, in an effort to help overcome these challenges. This innovative pilot program will explore new ways to transform care by generating novel insights into the patient experience that physicians can directly utilize."

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing